Clinical Trials Logo
  1. Home
  2. Chronic Kidney Disease
  3. NCT04350944

FGF-23 and PTH in Hemodialysis Patients

Chronic Kidney Disease Requiring Chronic Dialysis Clinical Trial

Official title:
FGF-23 and PTH During Hemodialysis Patients Under Consideration of Calcification Propensity - a Pilot Study

Clinical Trial Summary

In this pilot study the investigator will examine the levels of fibroblast growth factor (FGF-23) and parathyroid hormone (PTH) levels during hemodialysis therapy in 30 patients and assess the correlation between these parameters and the T-50 calcification propensity, as well as further parameters of secondary hyperparathyroidism (sHPT), like serum calcium (sCa), phosphate (P), 25-hydroxy-vitamin D (25(OH)D) and 1,25 dihydroxy-vitamin D (1,25(OH)2D). The investigator hypothesize that FGF-23 and PTH levels are at their highest at the beginning of dialysis and decrease during the treatment.

Clinical Trial Description

Background: The development of sHPT in hemodialysis patients is a common complication which induces an increase in calcification and atherosclerosis. Elevated FGF-23 levels are already found in early stages of chronic kidney disease (CKD) and it has been shown that high FGF-23 levels are associated with the development of cardiovascular disease and increased overall mortality. Method: In this pilot study a total number of 30 patients on maintenance haemodialysis will be enrolled. The investigator will examine the course of FGF-23 and PTH levels during a single hemodialysis session. In addition, the T-50 time, a novel non-traditional cardiovascular risk factor as well as further parameters of sHPT, such as serum calcium (sCa), phosphate (P), 25-hydroxy-vitamin D (25(OH)D) and 1,25 dihydroxy-vitamin D (1,25(OH)2D) will be assessed. Hypothesis and specific aims: The major end point of the study is the level of FGF-23 and PTH at three points during hemodialysis treatment. As secondary end points the T-50 calcification propensity and further parameters of sHPT, as well as the correlation between these parameters will be measured. Hemodialysis is classified as a kidney replacement therapy and FGF-23 and PTH are partly metabolized and excreted by the kidneys. Based on this the investigator hypothesize that FGF-23 and PTH levels are at their highest at the beginning of dialysis and decrease during the treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04350944
Study type Observational [Patient Registry]
Source Medical University of Vienna
Contact
Status Completed
Phase
Start date January 14, 2020
Completion date August 31, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT05700851 - Immuno-nutrition Supplementation in Haemodialysis N/A
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Completed NCT01464190 - A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients Phase 3
Recruiting NCT06040281 - Smart and Fit for Kidney Transplantation N/A
Active, not recruiting NCT03535922 - Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care N/A
Completed NCT04622709 - Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis Phase 2
Completed NCT04585607 - Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia Phase 4
Completed NCT03182699 - Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Phase 4
Completed NCT03942744 - The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function. N/A
Completed NCT04549597 - Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Phase 4
Recruiting NCT04659525 - Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia Phase 4
Completed NCT04125537 - Pathways Project: Kidney Supportive Care
Recruiting NCT03347773 - Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity N/A
Recruiting NCT04397653 - Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients Phase 4
Active, not recruiting NCT03938285 - Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal N/A
Completed NCT03525223 - Modulation of Tissue Sodium in Hemodialysis Patients N/A
Completed NCT01324128 - A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients Phase 3
Not yet recruiting NCT04600193 - a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT06225544 - Lumasiran in Hyperoxalaemic Patients on Haemodialysis Phase 2
Recruiting NCT05209880 - Advance Care Planning in the Emergency Department N/A